{"id":"NCT00423319","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)","officialTitle":"A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2007-01-18","resultsPosted":"2014-05-14","lastUpdate":"2014-05-14"},"enrollment":5407,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Deep Vein Thrombosis","Pulmonary Embolism"],"interventions":[{"type":"DRUG","name":"Enoxaparin","otherNames":["Lovenox®"]},{"type":"DRUG","name":"Apixaban","otherNames":["BMS-562247","Eliquis®"]},{"type":"DRUG","name":"Enoxaparin-matching placebo","otherNames":[]},{"type":"DRUG","name":"Apixaban-matching placebo","otherNames":[]}],"arms":[{"label":"Apixaban, 2.5 mg BID plus placebo","type":"ACTIVE_COMPARATOR"},{"label":"Enoxaparin, 40 mg QD plus placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban compares with enoxaparin in preventing these clots. The safety of apixaban will also be studied","primaryOutcome":{"measure":"Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period","timeFrame":"Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose","effectByArm":[{"arm":"Apixaban, 2.5 mg BID Plus Placebo","deltaMin":1.39,"sd":null},{"arm":"Enoxaparin, 40 mg QD Plus Placebo","deltaMin":3.86,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":143,"countries":["United States","Argentina","Australia","Belgium","Canada","China","Denmark","France","Germany","Hungary","India","Israel","Mexico","Norway","Poland","Romania","Russia","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["35570249","23279103","21175312"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":184,"n":2673},"commonTop":["Nausea","Procedural pain","Constipation","Hypotension","Pyrexia"]}}